A carregar...

Preclinical and Clinical Experience with Dasatinib in Philadelphia Chromosome-Negative Leukemias and Myeloid Disorders

Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph−) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived gro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Autor principal: Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428150/
https://ncbi.nlm.nih.gov/pubmed/19013641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.10.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!